Arcutis Biotherapeutics, Inc.

ARQT

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001628280-26-014639
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026
Reporting Owners: Welgus Howard G. (Director)

Summary

Type

Sell

Net shares

-10,000

% of shares

-16.74%

Amount (USD)

$256,518

Insider confidence score

20.0 out of 100

Positive

  • Under Rule 10b5-1 trading plan

Negative

  • Massive scheduled sell (<20% of shares)
  • Large sell amount ($250K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-10,000.0

Price per Share

$25.65

Amount (USD)

$256,518.00

Acquired/Disposed

Disposed

Shares Owned Before

59,744.0

Shares Owned After

49,744.0

Filing's footnotes

1. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.37 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

ℹ️ Filed under Rule 10b5-1 trading plan

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.